四環醫藥：中期報告2024.pdf

1、中期報告INTERIM REPORTSihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司(incorporated in Bermuda with limited liability)（於百慕達註冊成立之有限公司）Stock Code 股份代號：0460公司簡介CORPORATE PROFILE四環醫藥控股集團有限公司（四環醫藥 或 本公司，連同其附屬公司為 本集團）（股份代號：00460.HK）創立於二零零一年，二零一零年於香港聯合交易所有限公司主板上市，是一家以創新為引領，堅持創新驅動，擁有獨立領先的自主生產、研究與開發（研發）技術平台

2、，具備豐富的全球化產品管線和成熟卓越銷售體系的國際化醫美及生物製藥企業。四環醫藥聚焦醫美、腫瘤、代謝、糖尿病、心腦血管、現代中藥及工業大麻等高增長治療領域，一直秉承堅持全速推進四環醫美及生物製藥雙輪驅動戰略 的整體戰略目標來打造中國領先的醫美及生物製藥企業。Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010,Sihuan Pharmaceutical Holdings Group Ltd.(“Sihuan Pharmaceutical”or the“Com

3、pany”,together with its subsidiaries,the“Group”)(Stock Code:00460.HK)is an international medical aesthetic and biopharmaceutical company led and driven by innovation,with a leading independent production,and research and development(“R&D”)technology platform,a rich global product pipeline and a matu

4、re and excellent sales system.Focusing on high-growth therapeutic areas such as medical aesthetics,oncology,metabolism,diabetes,cardiovascular and cerebrovascular,modern Chinese medicine and industrial hemp,it adheres to its overall strategic objective of“Adhering to the full-speed promotion of a tw

5、o-wheeled strategy of Sihuan medical aesthetics and biopharmaceuticals”to build a leading medical aesthetics and biopharmaceutical enterprise in China.2公司資料Corporate Information4管理層討論及分析Management Discussion and Analysis40其他資料Other Information58獨立審閱報告Independent Review Report60中期簡明綜合損益及其他全面收益表Interi

6、m Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income目錄CONTENTS62中期簡明綜合財務狀況表Interim Condensed Consolidated Statement of Financial Position64中期簡明綜合權益變動表Interim Condensed Consolidated Statement of Changes in Equity66中期簡明綜合現金流量表Interim Condensed Consolidated Statement of C